<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Personalized and Precision Medicine Journal</title>
    <link>https://www.pmjournal.ir/</link>
    <description>Personalized and Precision Medicine Journal</description>
    <atom:link href="" rel="self" type="application/rss+xml"/>
    <language>en</language>
    <sy:updatePeriod>daily</sy:updatePeriod>
    <sy:updateFrequency>1</sy:updateFrequency>
    <pubDate>Thu, 01 May 2025 00:00:00 +0330</pubDate>
    <lastBuildDate>Thu, 01 May 2025 00:00:00 +0330</lastBuildDate>
    <item>
      <title>The Multifaceted Role of CD154 in SLE: Pathogenesis, Receptor Interactions, and Emerging Therapies</title>
      <link>https://www.pmjournal.ir/article_723301.html</link>
      <description>Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by immune dysregulation and multi-organ involvement. Central to its pathogenesis is the CD154/CD40 signaling axis, which orchestrates key immunological processes, including T-B cell collaboration, dendritic cell activation, and cytokine production. Recent findings have expanded the scope of CD154 beyond its classical receptor CD40, identifying integrins as alternative receptors, thus broadening its biological impact. These discoveries underline the complexity of CD154's role in SLE and its potential as a therapeutic target. First-generation CD154/CD40-targeted therapies showed promise but were hindered by thromboembolic complications. However, second-generation therapeutics, including monoclonal antibodies, small molecules, and gene-editing technologies, exhibit improved safety and efficacy profiles. This review delves into the molecular and cellular mechanisms of CD154 in SLE, explores its emerging roles through integrin interactions, and evaluates the therapeutic advancements targeting this axis. The findings highlight CD154 as a central mediator in SLE pathogenesis and a compelling target for innovative treatment strategies.</description>
    </item>
    <item>
      <title>An Ethnographic Review of Medicinal Plants Used for Alleviating Menstrual Pain in the Western Border Ethnobotany of Iran</title>
      <link>https://www.pmjournal.ir/article_723302.html</link>
      <description>Introduction: In this context, the use of medicinal plants as a natural and effective remedy for relieving Menstrual pain has been acknowledged in the western border region of Iran, serving as an alternative or complementary therapeutic approach. The aim of this study is to identify the medicinal plants employed in this region of Iran for the treatment of menstrual pain.Methodology: This review study employed keywords such as medicinal plants, Iran, menstrual pain, and the provinces of West Azerbaijan, East Azerbaijan, Ardabil, Kurdistan, Kermanshah, Ilam, Khuzestan, and their cities, along with ethnobotany terms. Databases such as Google Scholar, SID, MegaIran, PubMed, and Scopus were utilized for article searches. Ethnobotanical articles related to the topic were selected for text review.Results: Based on the ethnobotanical review, it was identified that in the cities and provinces of the western border region of Iran, medicinal plants such as fennel, wild parsley, shepherd's purse, black cumin, thyme, dandelion, rue, safflower, myrtle, European hornbeam, Kurdistan pistachio, mint, marshmallow root, male orchid, yarrow, agrimony, nettle, bitter herb, verbena, horsetail, periwinkle, marigold, saffron, wild thyme, savory, rhubarb, and eastern chamomile are commonly used for managing, controlling, and treating menstrual pain. Notably, the highest diversity of plant species was observed in the regions of Behbahan, Khuzestan, and Zrewar, Kurdistan. Leaves were the most commonly used plant part, and the Asteraceae and Lamiaceae families presented the highest number of species, indicating the rich diversity of medicinal and traditional plant applications.Conclusion: The findings of this study demonstrate that the local communities in the western border region of Iran possess extensive knowledge regarding the use of medicinal plants for alleviating menstrual pain. Documenting and scientifically exploring this knowledge could lay the groundwork for the development of effective and natural herbal medicines in the domain of women&amp;amp;rsquo;s health.</description>
    </item>
    <item>
      <title>The Use of Bacteriophages in Cancer Therapy</title>
      <link>https://www.pmjournal.ir/article_717368.html</link>
      <description>Cancer is a catastrophic illness with a significant worldwide fatality rate, anticipated to rise in the next years. Contemporary treatment modalities, including chemotherapy and radiation therapy, include constraints such as adverse effects, inconsistent efficacy, elevated expenses, and restricted accessibility. Bacteriophages have arisen as multifaceted instruments in bioengineering, with significant promise in tissue engineering, vaccine formulation, and immunotherapy. Bacteriophages are being used extensively in several fields of biotechnology and medicine, with cancer treatment being the most compelling application. Numerous studies are increasingly validating the effectiveness and safety of phage-based vectors as systemic delivery vehicles for therapeutic genes and medicines in cancer treatment. Moreover, the genetic composition of phages may be used for the creation of innovative DNA vaccines and antigen display systems, since they provide a highly structured and repeated presentation of antigens to immune cells. Bacteriophages have created novel opportunities for the precise targeting of certain molecular determinants in cancer cells. Phages may serve as anticancer agents and as carriers for imaging compounds and medicines. This article introduces bacteriophage and examines the performance of bacteriophages and bacteriophage engineering in targeted cancer treatment.</description>
    </item>
    <item>
      <title>Association of FGFR2 Gene Polymorphisms (rs2981582 and rs1219648) with Breast Cancer Susceptibility in Iranian Women: A Case-Control Study with Haplotype and Expression Analysis</title>
      <link>https://www.pmjournal.ir/article_735666.html</link>
      <description>Background: Breast cancer is the most common malignancy among women in Iran, characterized by a relatively early age of onset and a rising incidence rate. The single-nucleotide polymorphisms rs2981582 and rs1219648, located in intron 2 of the FGFR2 gene, have been linked to breast cancer susceptibility in genome-wide association studies (GWAS). Nevertheless, their significance in the Iranian population has not been extensively investigated.This study investigates the association of FGFR2 polymorphisms (rs2981582 and rs1219648) with breast cancer risk in Iranian women, alongside haplotype interactions and gene expression profiling.Methods: A case-control study was conducted with 160 participants (80 cases and 80 age-matched controls). FGFR2 SNPs were genotyped with PCR-RFLP. Chi-square tests were used to analyze associations of haplotypes. FGFR2 expression was evaluated in breast cancer subtypes using GEO (GDS2635, GDS3853) and Expression Atlas datasets. Statistical analyses were carried out using SPSS version 22.0 (IBM Corp., Armonk, NY, USA), with statistical significance defined as P&amp;amp;lt;0.05. Hardy&amp;amp;ndash;Weinberg equilibrium (HWE) was verified for both SNPs in the control group (P&amp;amp;gt;0.05).Results: The TT genotype of rs2981582 was significantly associated with increased breast cancer risk (P=0.00; OR=3.566). No independent association was found for rs1219648 (P&amp;amp;gt;0.05). Haplotypes AC and AT were significantly associated with elevated risk (P=0.004 and P=0.001, respectively). FGFR2 expression was upregulated in lobular carcinoma and downregulated in ductal carcinoma compared to healthy controls (P&amp;amp;lt;0.05).Conclusion: The rs2981582 TT genotype and specific haplotypes (AC, AT) are associated with increased breast cancer risk in Iranian women, supporting FGFR2 as a potential biomarker for early detection and personalized risk assessment in this population.</description>
    </item>
    <item>
      <title>Pituitary hormones Profile, Cholesterol Levels, and Steroidogenic Genes Xxpression are Useful Information in Prostate Cancer</title>
      <link>https://www.pmjournal.ir/article_735667.html</link>
      <description>Objective: To investigate the relationship between changes in the level of Pituitary hormones, cholesterol levels, and the expression of genes involved in the biosynthesis of androgens, this study was designed.Methods: In this study, the amount of changes in the levels of LH, FSH, and PRL hormones, as well as the level of cholesterol as a precursor of androgens, LDL and HDL lipoproteins, and the expression level of two genes, CYP17A1 and CYP11A1, in 120 people with prostate cancer as a case group and 120 people with BPH as a control group by RT-qPCR. Results: The statistical analysis demonstrated that serum levels of testosterone, LH, and TSH were significantly higher in the malignant group compared to the benign group. PRL levels were also elevated in the Prostate cancer (PCa) group; however, this difference did not reach statistical significance. No significant difference was observed in serum PSA levels between the two groups. Prostate volume was significantly greater in the benign group than in the malignant group. Serum cholesterol levels were significantly higher in the PCa group compared to the Benign prostatic hyperplasia (BPH) group. In contrast, serum levels of LDL and HDL lipoproteins showed no significant differences between the groups. Additionally, the expression levels of CYP11A1 and CYP17A1 genes were significantly increased in the PCa group relative to the BPH group. Conclusion: The results of this study showed that monitoring the hormonal profile and cholesterol level can play an important role in predicting the course of the disease.</description>
    </item>
    <item>
      <title>Examining the Autoimmune Disorder Rheumatoid Arthritis and the Genetic Determinants Contributing to its Genesis</title>
      <link>https://www.pmjournal.ir/article_735669.html</link>
      <description>Rheumatoid arthritis (RA) is an irreversible systemic autoimmune disorder. The advancement of the illness results in joint deformity and associated functional impairment, which profoundly impacts the standard of life of those affected. This review offers an overview of rheumatoid arthritis (RA), including a broad introduction to the illness, its epidemiology, associated risks, and pathogenesis. It also emphasizes advancements in fundamental research and the many mechanisms of signaling and molecular processes, including genetic variables. Summary of previous studies: In recent decades, researchers have garnered more interest in rheumatoid arthritis. Aberrant signaling pathways in rheumatoid arthritis (RA) constitute a significant area of study for identifying and treating the condition, offering crucial insights for comprehending this complex illness and formulating relevant therapies. The etiology of rheumatoid arthritis is associated with several signaling pathways. Research has repeatedly examined the etiology of rheumatoid arthritis (RA), revealing that both environmental and genetic variables play significant roles in its onset. Additionally, several research indicates that the susceptibility and severity of rheumatoid arthritis (RA) may correlate with the HLA-DRB1 variant, which exhibits the most significant genetic relationship with RA.</description>
    </item>
    <item>
      <title>A Personalized Medicine Approach to Microbiome Analysis Aimed at Characterizing the Gut Microbiome</title>
      <link>https://www.pmjournal.ir/article_735670.html</link>
      <description>The human gut microbiome constitutes a highly diverse and unique ecosystem that plays a critical role in shaping host metabolism, immune function, and vulnerability to numerous diseases. Thanks to recent breakthroughs in high-throughput sequencing, shotgun metagenomics, and integrative multi-omics strategies, researchers can now achieve comprehensive profiling of microbial communities with strain-level precision and detailed functional insights. Specific microbial patterns have emerged as reliable predictive biomarkers for assessing disease risk, tracking progression, and determining treatment outcomes in various conditions, including metabolic syndrome, inflammatory bowel disease, autoimmune disorders, and cancer. By combining microbiome data with host genomics, metabolomics, and clinical metrics, precision medicine is enhanced, facilitating tailored interventions such as dietary changes, probiotics, prebiotics, and fecal microbiota transplantation. Sophisticated bioinformatics tools, alongside machine learning and artificial intelligence, streamline the analysis of complex, high-dimensional multi-omics data, helping to pinpoint crucial microbial taxa, functional pathways, and predictive markers. Nevertheless, significant hurdles persist regarding the standardization of sample collection, sequencing protocols, bioinformatic workflows, and reproducibility across different study cohorts. Additionally, ethical issues such as data privacy, informed consent, and fair access require careful attention. Future studies that integrate longitudinal multi-omics profiling, mechanistic investigations of host microbe interactions, and robust clinical validation of microbial biomarkers are expected to propel microbiome-driven personalized medicine forward. Ultimately, a thorough characterization of the gut microbiome offers a revolutionary approach to proactive, patient-centric healthcare, shifting focus from general population-based models to precise, individualized strategies for prevention, diagnosis, and therapy.</description>
    </item>
    <item>
      <title>Investigation of Gene Expression and DNA Methylation of IGF2, PPAR&amp;gamma;, LEP, and CDKN1C in Gestational Diabetes Mellitus</title>
      <link>https://www.pmjournal.ir/article_735672.html</link>
      <description>Gestational diabetes mellitus (GDM) is a prevalent complication of pregnancy associated with adverse outcomes for both mother and fetus. Epigenetic modifications, particularly DNA methylation, may play a significant role in its pathogenesis. This study aimed to evaluate the expression and methylation status of IGF2, PPAR&amp;amp;gamma;, LEP, and CDKN1C in women with GDM. In this case control study, 50 women with GDM and 50 healthy pregnant women were included. Gene expression levels and DNA methylation patterns were analyzed, and clinical risk factors were assessed. Significant differences were identified in both expression and methylation profiles of the studied genes between GDM patients and controls. Pre-pregnancy BMI, high-fat diet, and family history of diabetes were significantly associated with GDM. These results indicate that GDM is influenced by metabolic, environmental, and epigenetic factors, and that altered expression and methylation of IGF2, PPAR&amp;amp;gamma;, LEP, and CDKN1C may contribute to its development.</description>
    </item>
    <item>
      <title>Pentagalloylglucose Suppresses Glioblastoma Progression via Wnt/&amp;beta;-Catenin Pathway Inhibition and EMT Reversal</title>
      <link>https://www.pmjournal.ir/article_735673.html</link>
      <description>Background: Glioblastoma multiforme (GBM) is the most lethal primary brain tumor. GBM exhibits rapid growth and invasiveness along with a nadir prognosis. Epithelial&amp;amp;ndash;mesenchymal transition (EMT), combined with activated Wnt/&amp;amp;beta;-catenin signaling, contributes to GBM progression and associated therapy resistance. Pentagalloylglucose (PGG), a polyphenolic compound from nature, has been shown to be anticancer in multiple cancers by inhibiting proliferation, migration, and EMT. The objectives are to demonstrate the effects of PGG on GBM cells and examine the modulation of EMT and the Wnt/&amp;amp;beta;-catenin pathway. Methods: U87-MG cells were treated with PGG (0.5&amp;amp;ndash;40 &amp;amp;micro;M) for 24, 48, and 72 hours. Cell viability was assessed using the MTT assay. The expression levels of epithelial&amp;amp;ndash;mesenchymal transition (EMT) markers, including E-cadherin, N-cadherin, Vimentin, Snail, Slug, as well as &amp;amp;beta;-catenin, were quantified by qRT-PCR. Cell migration was evaluated using a wound healing assay. Statistical analysis was performed using one-way ANOVA followed by Tukey&amp;amp;rsquo;s post hoc test.Results: PGG demonstrated a marked reduction in cell viability in a dose- and duration-dependent manner with IC₅₀ values at 18.4, 12.7, and 8.9 &amp;amp;micro;M at 24, 48, and 72 hours, respectively. The upregulation of E-cadherin and downregulation of N-cadherin, Vimentin, and the Snail protein show that mesenchymal markers are being transcriptionally silenced. It was also a striking loss of &amp;amp;beta;-catenin expression, which suggests Wnt/&amp;amp;beta;-catenin suppression. Wound healing assay showed that PGG treatment resulted in a marked reduction of cell migration.Conclusion: PGG significantly inhibits the progression of GBM by inhibiting EMT and downregulating the Wnt/&amp;amp;beta;-catenin signaling pathways. Overall, PGG has potential as a natural, low-toxicity therapeutic or combinatory drug for glioblastoma, and future studies in vivo and in human trials will be needed to reaffirm this conclusion.</description>
    </item>
    <item>
      <title>The Role of Hormonal Therapy in the Management of Hormone Receptor-Positive Breast Cancer: Current Trends and Future Directions</title>
      <link>https://www.pmjournal.ir/article_735775.html</link>
      <description>Breast cancer is responsible for more than 2.3 million newly diagnosed cases each year, according to the statistics. A hormonal imbalance, which is defined by unregulated activity of estrogen and progesterone, is often the cause of this type of cancer. It has become easier to handle patients who have HR+ breast cancer, particularly in women who have both advanced and early-stage disease, as a result of the deployment of estrogen-blocking hormone treatment. The permissiveness of tamoxifen, which was the first selective estrogen receptor modulator (SERM) to be commercialized, made it possible for more hormonal therapies to be developed. The cornerstone of breast cancer treatment is comprised of aromatase inhibitors (AIs), selective estrogen receptor degraders (SERDs), and cyclin-dependent kinase inhibitors (CDK) 4/6. These three types of drugs ultimately lead to improved patient outcomes. On the other hand, the inherent or acquired resistance of cancers to hormone therapy continues to be a serious cause for concern. Alterations in the genetic makeup of the tumor, as well as the activation of alternate pathways, make this situation even worse. The increasing development of molecular biology, precision medicine, and targeted therapies, on the other hand, is pointing to a new strategy for dealing with these problems. The purpose of this study is to investigate prospective treatment options and to shed light on the significant role that hormone therapy plays in the management of HR-positive breast cancer.</description>
    </item>
    <item>
      <title>Comparison of Hemodynamic Changes and Post-Anesthesia Pain Intensity in Premenopausal and Postmenopausal Women Undergoing Elective Abdominal Hysterectomy with General Anesthesia</title>
      <link>https://www.pmjournal.ir/article_735776.html</link>
      <description>Background: Menopause comes along with a set of hormonal and physiological changes that can change cardiovascular responses during surgeries, along with altering pain perception. This research intends to analyze pain intensity during and after anesthesia and changes in hemodynamics in pre- and post-menopausal women during elective abdominal hysterectomy under general anesthesia.
Methods: Elective surgery patients, in this case, were 88 in number, with each division having 44 patients (before menopause and after). Women in each group were defined as premenopausal (n=44) and postmenopausal (n=44) in equal proportion. Other metrics looked at were Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP), also known as SpO₂. Patients’ heart rate and SpO₂ were checked during the surgery and after the surgery as well. Pain was assessed with the use of standardized scale methods, and participants were questioned on the pain felt during the post-operative period.
Results: While the premenopause cohort showed lower fluctuations in sensitivity to changes in SBP, DBP, and HR during and after anesthesia, the Postmenopause cohort exhibited the opposite (p&amp;amp;lt;0.05). In each group, the SpO₂ levels were maintained within normal limits and showed no significant group differences. In the postoperative period, the pain score was significantly higher in the postmenopausal group with lower pain tolerance and a higher requirement for analgesic treatment. Spoken demographics such as age, body mass index (BMI), and other associated conditions showed a moderating influence on the hemodynamic response and pain outcomes.
Conclusion: Following menopause, diminished vascular adaptability, along with increased sympathetic tone and decreased central pain modulatory control due to lack of estrogen, might explain the instability of hemodynamics and increased postoperative pain. These observations could help in the formulation of appropriate anaesthetic techniques and postoperative pain relief policies in relation to the reproductive status of women.</description>
    </item>
  </channel>
</rss>
